CABTREO

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Oct 20, 2023

   2 yr 8 mo ago

2. Today

3. Exclusivity ends · NP

   New product exclusivity (3 years)

   Oct 20, 2026

   in 4 mo

4. Patent 10220049 expires

   Listed drug product patent expiration.

   Jun 03, 2029

   in 3 yr

5. Patent 10624918 expires

   Listed method-of-use patent (U-3713) expiration.

   Jun 03, 2029

   in 3 yr

6. Patent 9561208 expires

   Listed drug product patent expiration.

   Jun 03, 2029

   in 3 yr

7. Patent 8288434 expires

   Listed drug product patent expiration.

   Aug 05, 2029

   in 3 yr 2 mo

8. Patent 12128059 expires

   Listed drug product patent expiration.

   Jul 31, 2040

   in 14 yr 4 mo

9. Patent 12133859 expires

   Listed drug product patent expiration.

   Jul 31, 2040

   in 14 yr 4 mo

10. Patent 12138278 expires

    Listed drug product patent expiration.

    Jul 31, 2040

    in 14 yr 4 mo

11. Patent 12616710 expires

    Listed drug product patent expiration.

    Jul 31, 2040

    in 14 yr 4 mo

12. Patent 11389467 expires

    Listed drug product patent expiration.

    Dec 28, 2040

    in 14 yr 9 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NPNew product exclusivity (3 years)

  Oct 20, 2026

  in 4 mo

Listed patents (9)